Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.
FORGE NEW CHEMISTRY
Distinct from traditional approaches for ‘hit’ discovery using high throughput screens, the FORGE approach starts with metal-ligand interactions to identify selective metal-binding pharmacophore fragments from our proprietary library. Using bio-inorganic and medicinal chemistry principles, full-length inhibitors are developed using a novel fragment growth strategy incorporating computational and structural biology.
FORGE NEW MEDICINES
Shining a light on a problem from a different direction can reveal undiscovered solutions.
At FORGE, we are uniquely discovering compounds that have potential for first-in-class medicines.
FORGE LPXC PROGRAM
LpxC has been recognized as an attractive antibacterial target for more than the past 15 years as it is conserved across Gram-negative bacteria and not found in Gram-positive bacteria or human cells. However, a lack of suitable chemical starting points has hampered development progress. Forge has utilized its proprietary metal-binding pharmacophore (“MBP”) library and processes to identify potent inhibitors of LpxC that are safe and effective in an animal model of Gram-negative infection and are able to kill Gram-negative superbugs where other antibiotics are ineffective.
WE ARE FORGE
Forge was founded by leading bio-inorganic scientists and industry experts with the vision of creating a significant biotechnology company that couples pioneering metalloprotein technology with rigorous research to create life-saving medicines in areas of high unmet needs.
Zachary Zimmerman, Ph.D.
Chief Executive Officer
David Puerta, Ph.D.
Chief Operating Officer and Vice President of Discovery
Esther van de Boom
Min Teng, Ph.D.
Vice President, Chemistry
Konstantin Taganov, Ph.D.
Principal Scientist, Biology
Baskar Nammalwar, Ph.D.
Research Scientist II, Chemistry
Xiaoming Li, Ph.D.
Principal Scientist, Chemistry
Seth Cohen, Ph.D.
Professor of Chemistry, University of California San Diego Click here to learn more
David Puerta, Ph.D.
Chief Operating Officer and Vice President of Discovery Click here to learn more
BOARD OF DIRECTORS
Brian DorseyPartner of MagnaSci Ventures
Mario PolywkaCOO of Evotec AG
John SchmidFormer CFO of Trius and Auspex Pharmaceuticals
Steve Worland, Ph.D.President and CEO of eFFECTOR Therapeutics
Zachary ZimmermanCEO of Forge
SCIENTIFIC ADVISORY BOARD
Michael Barbachyn, Ph.D.,co-inventor of the antibiotics linezolid (marketed as Zyvox) and sutezolid, and former director-level contributor to antibacterial discovery at Pharmacia, Pfizer and AstraZeneca.
Robert Bonomo, M.D.,Chief Medical Service at Louis Stokes Cleveland VA Medical Center, and Professor of Medicine at Case Western Reserve University.
Seth Cohen, Ph.D.,scientific co-founder of Forge and one of the world’s leading authority on metalloprotein inhibitors; Professor and former Chair of the Department of Chemistry and Biochemistry at the University of California, San Diego.
John Rex, M.D.,Chief Medical Officer and Director at F2G Ltd. and Chief Strategy Officer at CARB-X, the world’s largest public-private partnership devoted to antibacterial preclinical R&D.
Karen Joy Shaw, Ph.D.,current Chief Scientific Officer of Amplyx Pharmaceuticals and former SVP Biology at Trius Therapeutics leading the microbiology strategy for Tedizolid development; former Antibacterial Team Leader Johnson & Johnson and Schering Plough.
Lynn Silver, Ph.D.,was involved in the discovery of the first inhibitors of LpxC, and the development of the antibiotic Invanz at Merck where she held the title of senior investigator.
Brad Spellberg, M.D.,Chief Medical Officer, LA+USC Medical Center and antibiotic resistance expert.
Andrew Tomaras, Ph.D.,Vice President and Director of Microbiology at BacterioScan Inc. and former LpxC program leader at Pfizer.
Mark Whittaker, D.Phil.,SVP Drug Discovery at Evotec and former Director Medicinal Chemistry at British Biotech.
Partners and Investors
Forge Therapeutics, Inc.
3210 Merryfield Row
San Diego, CA 92121